Stronger at Home: Improving Outcomes for Older Adults After Hip Fracture

ConditionHip Fractures
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age55+
SponsorDr. Mohammad Auais, PhD

About this trial

The goal of this clinical trial is to compare the effectiveness of a new 14-week individually-tailored home-based rehabilitation program called "Stronger at Home" with usual care in improving functional recovery in community-dwelling older adults after hip fractures.

The main question this trial aims to answer are:

• Is the Stronger at Home program more effective than usual care in improving functional recovery at the end of the 14-week intervention?

secondary questions include:

* What is the cost-utility of the Stronger at Home program compared to usual care at 3.5 months, 6 months, and 12 months after discharge? * Does the program have a sustained impact on functional recovery at 6 months and 12 months post-discharge?

Participants in the trial will be asked to engage in the following tasks:

* Participate in the Stronger at Home program, which includes using a self-directed toolkit consisting of educational resources and an illustrated exercise program. * Follow the guidelines provided in the toolkit for gradually increasing exercise intensity and incorporating different types of exercises into their daily life.

The effects of the Stronger at Home program will be compared to those of usual care.

Eligibility criteria

Qualifiers

Hip fracture patients who are 55 years or older,

Currently living in the community, and

Either being discharged to their home or a retirement home

Fall from a standing height or less

Disqualifiers

Came from long term care or discharged to long term care

Not a hip fracture (e.g., pelvic fracture)

Unable to give consent and no proxy

Fracture due to pathological disease (e.g., cancer, Paget's disease).

Trial design

Treatments tested in this trial

  • The Intervention (Stronger at Home Intervention)
  • Usual care (Control)

Treatment groups

200 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Dr. Mohammad Auais, PhD

Lead sponsor

Queen's University

Sponsor institution